← Back to Search

Intervention for Polycystic Kidney Disease (DIAT Trial)

N/A
Waitlist Available
Research Sponsored by McMaster University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 3 months
Awards & highlights

DIAT Trial Summary

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder. Tolvaptan has been approved in Canada as a treatment for ADPKD. Tolvaptan is an arginine vasopressin receptor antagonist which has been shown to decrease the progression of ADPKD. The main side effect of this treatment is increased urine output which leads to cessation of therapy in about 20% of patients. Low solute (low sodium, low protein) diet may alleviate this side effect. This is a single arm before / after study of dietary intervention on urine output and quality of life in ADPKD patients on a stable dose of tolvaptan.

Eligible Conditions
  • Polycystic Kidney Disease
  • Excessive Urination

DIAT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in 24-hour urine volume
Secondary outcome measures
Change in ADPKD-IS
Change in Nagasaki Diabetes Insipidus Questionnaire
Change in urine total solute

DIAT Trial Design

1Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
Single arm study. All participants will receive dietary intervention.

Find a Location

Who is running the clinical trial?

McMaster UniversityLead Sponsor
880 Previous Clinical Trials
2,597,820 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dietary Intervention in ADPKD on Tolvaptan
Peter Margetts 2019. "Dietary Intervention in ADPKD on Tolvaptan". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03858439.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top